Ziphius logo — Diving deeper to uncover the possibilities of self-amplifyin...

Ziphius

Diving deeper to uncover the possibilities of self-amplifying RNA.

Founded 2019 Belgium Belgium 60 employees Unknown Total: $24.30M Biotechnology, Pharmaceutical

General Information

Company Name Ziphius
Founded Year 2019
Location Belgium Belgium +1
Employees 60
Industries Biotechnology, Pharmaceutical
Funding Stage Unknown
Social

Get notified when Ziphius moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Ziphius

Ziphius, a Belgium-based company founded in 2019, operates in the Biotechnology and Pharmaceutical industries. Their mission, encapsulated in the slogan, "Diving deeper to uncover the possibilities of self-amplifying RNA," highlights their focus on innovative RNA technologies.

This startup has captured the attention of investors, with a notable €24.30M convertible note investment on 01 May 2021. Key investors include industry veterans Annie Vereecken and Christian Dumolin, signaling strong confidence in the company’s potential for growth and advancement in RNA research.

Taxonomy: self-amplifying RNA, biopharmaceutical, vaccine development, infectious disease prevention, next-generation vaccines, RNA technology, biotech innovation, vaccine biotechnology, therapeutic RNA

Services & Products

Development of self-amplifying RNA technologies
Innovative solutions for infectious diseases
Advanced treatments for rare diseases
Next-generation oncology therapies
Custom lipid nanoparticle delivery systems

Target Customers

Pharmaceutical companies Researchers in biotechnology Healthcare providers Oncology specialists Organizations focused on rare diseases

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Convertible Note •••••• 2 •••• •••• 01 May 2021

Ziphius Alternatives & Competitors

View All Alternatives
Ziphius vs

Delivering the potential of self-amplifying RNA (saRNA) therapeutics and vaccines.

2 employees
Ziphius vs

Personalized mRNA synthesis and therapeutics on-demand

Seed
1 employees
Biotechnology, Health and Wellness
Ziphius vs

Bring Innovative mRNA Vaccines to Life

Seed
14 employees
Biotechnology, Pharmaceutical

FAQ About Ziphius

Diving deeper to uncover the possibilities of self-amplifying RNA.
Ziphius was founded in 2019.
Ziphius is headquartered in Belgium.
Ziphius operates in the following industries: Biotechnology, Pharmaceutical.
Ziphius has approximately 60 employees.
Ziphius has completed 1 funding round, raising a total of $24.30M. The latest funding stage is Unknown.
Ziphius offers: Development of self-amplifying RNA technologies, Innovative solutions for infectious diseases, Advanced treatments for rare diseases, Next-generation oncology therapies, Custom lipid nanoparticle delivery systems.
Top alternatives and competitors to Ziphius include VaxEquity Ltd, Single Helix Genomics, Innovac Therapeutics, Circio Holding ASA , Orion Therapeutics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Ziphius and VaxEquity Ltd are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Ziphius and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

One analytics cookie (Google Analytics). Cookie Policy